The ELAINE-2 Study: Exploring New Treatments for Advanced ER+/HER2- Breast Cancer
Dr. Senthil Damodaran will discuss her ASCO22 poster “Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined with Abemaciclib (Abema) for Treating Pre-and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1Mutation After Progression on Prior Therapies.” She will share Sermonix Pharmaecuticals’ findings of the ELAINE-2 study, which explored the combination of lasofoxifene and the CDK4/6 inhibitor abemaciclib in postmenopausal women with ER+/HER2- metastatic breast cancer harboring ESR1 mutations. The study demonstrated promising results, showing a progression-free survival of 13 months and a clinical benefit rate of 69%. This Huddle will focus on the significance of targeting ESR1 mutations in the post-CDK4/6 inhibitor setting and its potential to fulfill the unmet need in this patient population.
Speaker
-
Senthil Damodaran, MD, PhD.
